GSA Capital Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

GSA Capital Partners’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13	Closed	-$57K	–	2013
2023 Q2	$57K	Buy	+13	New	+$45.1K	0.01%	1417
2023 Q1	–	Sell	-27	Closed	-$71K	–	2012
2022 Q4	$71K	Sell	27 -9	-25%	-$31.4K	0.01%	1334
2022 Q3	$141K	Buy	36 +29	+414%	+$114K	0.02%	1309
2022 Q2	$19K	Buy	+7	New	+$18.2K	﹤0.01%	1323
2021 Q4	–	Sell	-21	Closed	-$195K	–	1876
2021 Q3	$195K	Buy	+21	New	+$180K	0.02%	1248
2021 Q1	–	Sell	-7	Closed	-$40K	–	1571
2020 Q4	$40K	Hold	7	–	–	0.01%	1142
2020 Q3	$26K	Buy	+7	New	+$25.1K	﹤0.01%	1211

Other funds holding SEEL

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GSA Capital Partners's SEEL Position: Q3 2023 in Review

GSA Capital Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 13 shares — an estimated $57K sold.

GSA Capital Partners first reported a position in SEEL in Q3 2020 and held it in 7 quarters. The position peaked at $195K in Q3 2021. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

GSA Capital Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
GSA Capital Partners sold 13 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $57K.
GSA Capital Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
GSA Capital Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $195K in Q3 2021.
67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on GSA Capital Partners's 13F filing for Q3 2023, filed 15 Nov 2023.